Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

Major Program

Phase 0 I II Cancer Prevention Clinical Trials Program

Research Group

Breast and Gynecologic Cancer

Status

Completed

NCT ID

NCT02993159

This randomized phase IIB trial studies how well tamoxifen or afimoxifene works in treating patients with estrogen receptor positive breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate or afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells.

Intervention

Afimoxifene, Laboratory Biomarker Analysis, Placebo, Tamoxifen Citrate

Condition

Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive

Investigators

Seema Khan, MD

See list of participating sites